Canaccord raised the firm’s price target on GH Research (GHRS) to $39 from $35 and keeps a Buy rating on the shares. The firm noted the FDA lifted its clinical hold on GH001 (inhaled mebufotenin), which means the company is now on track to start a global Phase 3 program for treatment-resistant depression (TRD) in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- GH Research: Pivotal Pathway for GH001 in Treatment-Resistant Depression Supports $35 Target and Reiterated Buy Rating
- GH Research Wins FDA Clearance to Advance GH001 for Treatment-Resistant Depression
- GH Research: FDA Lifts Clinical Hold on GH001, Clearing Path to Phase 3 and Supporting Buy Rating
- GH Research to seek FDA alignment on Phase 3 program replicating Phase 2b design